Catheter Directed Thrombectomy and Other Deep Venous Interventions in Cancer Patients

Tech Vasc Interv Radiol. 2023 Jun;26(2):100900. doi: 10.1016/j.tvir.2023.100900. Epub 2023 Aug 5.

Abstract

Treating cancer patients with deep venous thrombosis/venous thromboembolism (DVT/VTE) can be challenging as patients are frequently unable to receive the standard therapy of anticoagulation due to the increased risk of bleeding complications seen in this population. Similarly, the hesitation of interventionalists to use thrombolytic agents due to bleeding risks limits percutaneous intervention options as well. Further, outcome data and guidelines do not exist for oncologic patients and often treatment is tailored to patient-specific factors after multidisciplinary discussion. This article reviews specific factors to consider when planning percutaneous treatment of cancer patients with DVT/VTE, focusing on the iliocaval system.

Publication types

  • Review

MeSH terms

  • Anticoagulants / adverse effects
  • Catheters / adverse effects
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / therapy
  • Thrombectomy / adverse effects
  • Thrombolytic Therapy / adverse effects
  • Treatment Outcome
  • Venous Thromboembolism* / therapy
  • Venous Thrombosis* / diagnostic imaging
  • Venous Thrombosis* / therapy

Substances

  • Anticoagulants